NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival?

nipec treatment

A mesothelioma treatment called NIPEC may help people with peritoneal mesothelioma live longer than expected. In some cases, much longer. A recent study of 74 peritoneal mesothelioma patients showed a combination of cytoreductive surgery (CRS), HIPEC, and NIPEC works better than CRS/HIPEC alone. The study comes from one of the country’s foremost medical authorities on peritoneal mesothelioma. Dr. Paul Sugarbaker runs the Peritoneal Surface Malignancy Program at Washington Cancer Institute in Washington, DC.  Last year, Dr. Sugarbaker released results of a small study on NIPEC treatment for mesothelioma. Although that study included only six patients, the results were impressive enough to warrant further study.  This year’s larger NIPEC study is even more promising for people fighting mesothelioma. Similarities and DIfferences … Continue reading NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival? »

Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests

triple-modality therapy

A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant pleural mesothelioma.  Pleural mesothelioma is an intractable cancer with a poor prognosis. It mainly affects people who have lived or worked around asbestos.  There is no cure for mesothelioma. People who have the best mesothelioma outcomes usually have a combination of treatments.  Now, scientists at Toronto General Hospital’s Research Institute say a triple-modality therapy they tested in mice might have the power to extend human lives, too. Multi-modal Mesothelioma Treatment Pleural mesothelioma is a fast-growing cancer that starts on the membrane around the lungs. Many mesothelioma patients die less than a year after diagnosis.  There is no single accepted treatment … Continue reading Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests »

Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study

maintenance therapy

Dutch researchers say administering maintenance therapy with gemcitabine after chemotherapy may help mesothelioma patients live longer than supportive care alone.  Gemcitabine is an antimetabolite sold under the brand name Gemzar. Oncologists use it to treat several other types of cancer. When cancer cells absorb gemcitabine, they can no longer divide into new cancer cells.  Most mesothelioma patients have chemotherapy as their first-line treatment. If they are healthy enough, they may also have mesothelioma surgery. A maintenance therapy is a treatment that follows the main treatment. It is an effort to maintain the effects of the treatment.  The new Dutch study shows gemcitabine may be a safe and effective choice for maintenance therapy. What Does Maintenance Therapy Mean? Right now, there … Continue reading Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study »

Cholesterol Drugs Extend Mesothelioma Survival in New Study

cholesterol drugs

Cholesterol drugs called statins have been shown to improve survival among mesothelioma patients taking PD-1 inhibitors.  The news comes from an international study from cancer researchers in Italy and the Netherlands.  More than 250 patients with pleural mesothelioma or non-small cell lung cancer were evaluated for the study. Researchers found that those who took cholesterol drugs while also receiving PD-1 blockers like Keytruda lived longer and had slower disease progression.  Mesothelioma Patients and Statins The body needs some cholesterol to build healthy cells. But many adults have too much cholesterol in their blood. This can lead to fatty deposits in the arteries that raise the risk for heart disease and stroke.  Cholesterol drugs called statins are designed to bring cholesterol … Continue reading Cholesterol Drugs Extend Mesothelioma Survival in New Study »

Induction Chemotherapy with Avastin Improves Mesothelioma Response in New Study

induction chemotherapy with Avastin

Mesothelioma patients who had induction chemotherapy with Avastin (bevacizumab) prior to surgery responded better than those who had only chemotherapy in a new Swedish study.  Researchers at the University Hospital Zurich analyzed the cases of 88 pleural mesothelioma patients who were slated to have surgery.  Most of the patients had standard chemotherapy before surgery. Some had induction chemotherapy with Avastin. Those who got the extra drug had a “significantly better response” according to a new report in Frontiers in Oncology. The Use of Induction Chemotherapy with Avastin or Without Induction chemotherapy is chemotherapy delivered before mesothelioma surgery. The goal of the treatment is to shrink the mesothelioma tumor as much as possible. This may improve the odds that surgeons can … Continue reading Induction Chemotherapy with Avastin Improves Mesothelioma Response in New Study »

Age is a Factor in Mesothelioma Survival After Surgery

mesothelioma survival after surgery

Age appears to be one of the biggest predictors of mesothelioma survival after surgery. This holds true no matter which kind of surgery a patient has.  A new study from the University of Pennsylvania compared the outcomes of more than 2,000 mesothelioma surgery patients. They compared them by surgical type. They also compared their survival with that of people who did not have surgery. Mesothelioma survival after surgery was consistently longer for younger patients. The risk of death within a few months went up a little bit with each year of age. The news could help patients and doctors make better treatment decisions. Surgical Procedures for Mesothelioma Operating on mesothelioma patients is controversial. Mesothelioma tumors are irregularly shaped and difficult to … Continue reading Age is a Factor in Mesothelioma Survival After Surgery »

Long-Term Mesothelioma Survival: Follow-up is Critical

long-term mesothelioma survival

A newly published French case report is a reminder that long-term mesothelioma survival requires long-term follow-up. The case comes from Aix-Marseille University in Marseille. In the Annals of Medicine and Surgery, doctors wrote about a man who survived mesothelioma for 14 years. In all that time, his cancer did not progress. The situation is unusual for mesothelioma. The life expectancy of most mesothelioma patients is about 18 months. Prolonged survival is two years or more. But the authors of the new report say their case shows that long-term mesothelioma survival is not impossible with the right approach. Treatment for Malignant Mesothelioma Malignant mesothelioma usually occurs in people who have lived or worked around asbestos. Many do not know they have … Continue reading Long-Term Mesothelioma Survival: Follow-up is Critical »

Multimodal Mesothelioma Treatment Doubles Survival in Mexican Study

multimodal mesothelioma treatment

Researchers at Mexico’s National Cancer Institute say multimodal mesothelioma treatment with chemotherapy, surgery, and radiation can slow tumor growth and improve survival. Their new study of patients with advanced pleural mesothelioma produced a median survival of nearly two years. That is almost twice as long as average for pleural mesothelioma.  The researchers say the key is a multimodal mesothelioma treatment approach that attacks tumors from three different angles. Chemotherapy Alone is Rarely Enough Chemotherapy is still the main treatment for most patients with pleural mesothelioma. The FDA approved pemetrexed (Alimta) in 2004. Until the recent approval of a combination of Opdivo and Yervoy, Alimta was the only drug for mesothelioma. It is still the main component in mesothelioma chemotherapy. But … Continue reading Multimodal Mesothelioma Treatment Doubles Survival in Mexican Study »

Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?

Keytruda and Tumor Treating Fields

There is hope that a new lung cancer trial combining Keytruda and Tumor Treating Fields could lead to a new treatment for pleural mesothelioma.  Recent studies show Keytruda (pembrolizumab) is one of the most promising immunotherapy drugs against malignant mesothelioma. Electrical device Tumor Treating Fields is only the second treatment to receive FDA approval for mesothelioma.  This summer, the manufacturers of these two treatments announced they would team up. They will test Keytruda and Tumor Treating Fields in patients with non-small cell lung cancer. The results could impact the future of mesothelioma treatment, too. Two Promising Therapies: Keytruda Keytruda is an immunotherapy drug. It blocks a protein called PD-1. Many types of cancer cells overproduce PD-1 to evade the immune … Continue reading Keytruda and Tumor Treating Fields: New Hope for Mesothelioma? »

First-Line Immunotherapy May Be Better Than Chemo for This Mesothelioma Subtype

First-Line Immunotherapy

A new study suggests that people with sarcomatoid mesothelioma may fare better if they have first-line immunotherapy before considering chemotherapy.  Chemotherapy is the standard first-line treatment for most people with mesothelioma. But a report in the journal Translational Lung Cancer questions the wisdom of that trend. The study focused on the outcomes of patients with the sarcomatoid mesothelioma subtype. These patients lived longer after immunotherapy than patients with other subtypes.  When first-line immunotherapy worked best, patients produced more white blood cells. Researchers say these patients might do well to avoid having chemotherapy first. Chemotherapy as Standard Mesothelioma Treatment First-line immunotherapy is not the typical mesothelioma treatment. Most mesothelioma patients have chemotherapy with Alimta (pemetrexed) before other treatments.  Alimta is the … Continue reading First-Line Immunotherapy May Be Better Than Chemo for This Mesothelioma Subtype »

Get your free copy of
“Surviving Mesothelioma” Today!